To Evaluate the Bioavailability of a Tablet of AZD1656

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the bioavailability of a tablet of AZD1656.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Male or female, type I diabetes patients, female with non child-bearing potential.

• Treated with insulin for more than 3 years. Well controlled HbA1c.

• Have a body mass index (BMI) ≥19 and ≤35

Exclusion Criteria:

• Clinically significant illness except type I diabetes, or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product

• Daily use of nicotine containing substances.